UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: Results from a phase I extension trial

European journal of cancer (1990), 2009-03, Vol.45 (4), p.579-587

2009

Volltextzugriff (PDF)

The Ras-Raf-MEK-ERK pathway in the treatment of cancer

Oncology research and treatment, 2002-12, Vol.25 (6), p.511-518

2002

Volltextzugriff (PDF)

86 Antitumoral Activity of a New Class of Triazenes

European journal of cancer (1990), 2012-11, Vol.48, p.27-28

2012

Volltextzugriff (PDF)

Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)

Annals of oncology, 2016-10, Vol.27 (10), p.1895-1902

2016

Volltextzugriff (PDF)

Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors

Annals of oncology, 2006-05, Vol.17 (5), p.866-873

2006

Volltextzugriff (PDF)

Pharmacokinetics of sorafenib in patients with renal impairment undergoing hemodialysis

International journal of clinical pharmacology and therapeutics, 2009-01, Vol.47 (1), p.61-64

2009

Volltextzugriff (PDF)

Pharmacokinetic study of sodium trans[tetrachlorobis(1H-indazole)-ruthenate (III)]/-indazole hydrochloride (1:1.1) (FFC14A) in patients with solid tumors

International journal of clinical pharmacology and therapeutics, 2009-01, Vol.47 (1), p.58-60

2009

Volltextzugriff (PDF)

Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors

International journal of clinical pharmacology and therapeutics, 2002-12, Vol.40 (12), p.580-581

2002

Volltextzugriff (PDF)

Plasma and cellular pharmacokinetics of doxorubicin after intravenous infusion of Caelyx/Doxil in patients with hematological tumors

International journal of clinical pharmacology and therapeutics, 2009-01, Vol.47 (1), p.55-57

2009

Volltextzugriff (PDF)

Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer

International journal of clinical pharmacology and therapeutics, 2010-07, Vol.48 (7), p.473-475

2010

Volltextzugriff (PDF)

Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer

International journal of clinical pharmacology and therapeutics, 2004-11, Vol.42 (11), p.650-651

2004

Volltextzugriff (PDF)

Novel antitumoral compound isolated from Clusia rosea

International journal of clinical pharmacology and therapeutics, 2003-12, Vol.41 (12), p.622-623

2003

Volltextzugriff (PDF)

Pharmacokinetics (PK) of a liposomal encapsulated fraction containing doxorubicin and of doxorubicin released from the liposomal capsule after intravenous infusion of Caelyx/Doxil

International journal of clinical pharmacology and therapeutics, 2005-12, Vol.43 (12), p.588-589

2005

Volltextzugriff (PDF)

A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors

International journal of clinical pharmacology and therapeutics, 2003-12, Vol.41 (12), p.620-621

2003

Volltextzugriff (PDF)

Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006

International journal of clinical pharmacology and therapeutics, 2003-12, Vol.41 (12), p.616-617

2003

Volltextzugriff (PDF)

Correlation of ERK-phosphorylation and toxicities in patients treated with the Raf kinase inhibitor BAY 43-9006

International journal of clinical pharmacology and therapeutics, 2004-11, Vol.42 (11), p.648-649

2004

Volltextzugriff (PDF)

Femoral head necrosis in three patients with relapsed ovarian cancer receiving high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation

Bone marrow transplantation (Basingstoke), 2003-03, Vol.31 (6), p.487-491

2003

Volltextzugriff (PDF)

Pharmacokinetics of treosulfan in a myeloablative combination with cyclophosphamide prior to allogeneic hematopoietic stem cell transplantation

International journal of clinical pharmacology and therapeutics, 2004-11, Vol.42 (11), p.654-655

2004

Volltextzugriff (PDF)

A new oxygen-enriched solution enables human tumor tissue transport without cell devitalization

International journal of clinical pharmacology and therapeutics, 2005-12, Vol.43 (12), p.586-587

2005

Volltextzugriff (PDF)

mproved viability of human tumor samples in a new oxygen-enriched solution

International journal of clinical pharmacology and therapeutics, 2004-11, Vol.42 (11), p.659-660

2004

Volltextzugriff (PDF)

ERK1/2 phosphorylation: a biomarker analysis within a phase I study with the new Raf kinase inhibitor BAY43-9006

International journal of clinical pharmacology and therapeutics, 2002-12, Vol.40 (12), p.567-568

2002

Volltextzugriff (PDF)

565 Antitumoral activity of a polyisoprenylated benzophenone (CLU-502) isolated from Clusia sp

European journal of cancer supplements, 2004-09, Vol.2 (8), p.172-172

2004

Volltextzugriff (PDF)

The influence of liver metastases on the pharmacokinetics of doxorubicin---a population-based pharmacokinetic project of the CESAR-APOH

International journal of clinical pharmacology and therapeutics, 2003-12, Vol.41 (12), p.598-599

2003

Volltextzugriff (PDF)

Circadian rhythm in the regulation of the MAP kinase pathway--pitfall in the determination of surrogate parameters?

International journal of clinical pharmacology and therapeutics, 2003-12, Vol.41 (12), p.614-615

2003

Volltextzugriff (PDF)

Differential increase in 12-HETE release and CD29/CD49f expression of platelets from normal donors and from patients with atopic dermatitis by Staphylococcus aureus

International archives of allergy and immunology, 1992-01, Vol.98 (4), p.339-342

1992

Volltextzugriff (PDF)

1 – 25 von 36

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(17)

Publikationsform

Artikel
(35)
Buchkapitel
(1)

Sprache

Englisch
(36)

Erscheinungsjahr

n.n

Thema

Humans
(25)
Biological And Medical Sciences
(12)
Medical Sciences
(12)
Science & Technology
(11)
Adult
(10)
Middle Aged
(10)
Niacinamide - Analogs & Derivatives
(10)
Phenylurea Compounds
(10)
Sorafenib
(10)
Aged
(9)
Female
(9)
Life Sciences & Biomedicine
(9)
Male
(9)
Pharmacology. Drug Treatments
(9)
Antineoplastic Agents
(7)
Chemotherapy
(7)
Dose-Response Relationship, Drug
(7)
Oncology
(7)
Benzenesulfonates - Pharmacology
(6)
Doxorubicin - Administration & Dosage
(6)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

6 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: Results from a phase I extension trial

The Ras-Raf-MEK-ERK pathway in the treatment of cancer

86 Antitumoral Activity of a New Class of Triazenes

Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)

Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors

Pharmacokinetics of sorafenib in patients with renal impairment undergoing hemodialysis

Pharmacokinetic study of sodium trans[tetrachlorobis(1H-indazole)-ruthenate (III)]/-indazole hydrochloride (1:1.1) (FFC14A) in patients with solid tumors

Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors

Plasma and cellular pharmacokinetics of doxorubicin after intravenous infusion of Caelyx/Doxil in patients with hematological tumors

Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer

Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer

Novel antitumoral compound isolated from Clusia rosea

Pharmacokinetics (PK) of a liposomal encapsulated fraction containing doxorubicin and of doxorubicin released from the liposomal capsule after intravenous infusion of Caelyx/Doxil

A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors

Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006

Correlation of ERK-phosphorylation and toxicities in patients treated with the Raf kinase inhibitor BAY 43-9006

Femoral head necrosis in three patients with relapsed ovarian cancer receiving high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation

Pharmacokinetics of treosulfan in a myeloablative combination with cyclophosphamide prior to allogeneic hematopoietic stem cell transplantation

A new oxygen-enriched solution enables human tumor tissue transport without cell devitalization

mproved viability of human tumor samples in a new oxygen-enriched solution

ERK1/2 phosphorylation: a biomarker analysis within a phase I study with the new Raf kinase inhibitor BAY43-9006

565 Antitumoral activity of a polyisoprenylated benzophenone (CLU-502) isolated from Clusia sp

The influence of liver metastases on the pharmacokinetics of doxorubicin---a population-based pharmacokinetic project of the CESAR-APOH

Circadian rhythm in the regulation of the MAP kinase pathway--pitfall in the determination of surrogate parameters?

Differential increase in 12-HETE release and CD29/CD49f expression of platelets from normal donors and from patients with atopic dermatitis by Staphylococcus aureus

Suchergebnisse filtern